This led Genomic Health to develop an online Recurrence Score Pathology-Clinical (RSPC) calculator to use in ER+/HER2-/node-negative breast cancer patients; RSPC combines RS with clinicopathological variables, including patient age, tumor size, tumor grade, and planned adjuvant hormonal therapy (tamoxifen or aromatase inhibitor) [18]. The gene discussed is CYP19A1; the disease is neoplasm.